Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.

Fifers planning to visit loved ones in hospital have been urged to make sure they are free of coughs, colds and other winter ...

Health officials have issued a '48-hour' plea to parents following a rise of norovirus cases in recent weeks, particularly ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...

Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...

A recent Indian Council of Medical Research (ICMR) study made some shocking revelations. It discovered that one in nine ...

Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. , a clinical-stage biotechnology company developing ...

As the air turns colder, wintertime illnesses are beginning to spread. In recent weeks, both Riverview Health and Eskenazi ...

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.

Contagious diseases like measles, COVID-19, influenza, norovirus, and tuberculosis pose significant global health challenges.

A hospital is "extremely busy" with growing numbers of norovirus, flu and Covid cases. University Hospitals Sussex NHS Foundation Trust said high numbers of people are attending Worthing Hospital. Due ...